Watch More Highlights
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, overall response rate, and very good partial response rate in older patients (65 years and older) with relapsed/refractory multiple myeloma (Abstract 1893).